

Investigating INR and APTTs: What can YOU do?

Jennifer Mills
Clinical Scientist:
Haematology and Transfusion.





SESSION AIMs

01. CLOTTING 101

Revision of clotting and its processes.

02. ABNORMAL INRs

Reasons for abnormal INRs and how they can be identified.

03. ABNORMAL APTRs

Reasons for abnormal APTRs and how they can be identified.

04. WHAT CAN YOU DO?

What tools do you have to investigate abnormal results?

WHY DO WE CLOT?

01. LIFE SAVING

Efficient clotting minimises blood loss after an injury.



02. INFECTION PREVENTION


By blocking the wound, the clot prevents pathogenic entry.




03. PROMOTES HEALING

By-products of clotting recruit immune cells and promote collagen and tissue development.

PRIMARY CLOTTING



SECONDARY CLOTTING



SECONDARY CLOTTING vs LAB TESTING

01. HOLISTIC

Secondary clotting happens in tandem with primary clotting.

02. NOT ONE OR THE OTHER.

Both intrinsic and extrinsic pathways are activated during the clotting cascade.

03. PLATELETS

Platelets are difficult to measure in laboratories but play a significant role in secondary clotting.


INTERNATIONAL NORMALISED RATIO: KEY FACTS

PROTHROMBIN TIME

Using reagent tissue factor, FVII is activated and triggers the common pathway.

INTERNATIONAL SENSITIVITY INDEX.

The ISI standardises all prothrombin reagents, which corrects for any biological variables.



$$INR = \left(\frac{PT_{\text{patient}}}{PT_{\text{meannormal}}} \right)^{ISI}$$

CLINICAL RELEVANCE?

Measures the **extrinsic** and **common** pathways. Used to monitor Vitamin K antagonists e.g. warfarin.

FACTORS ASSESSED

- FVII
- FX
- FV
- FXIII
- Prothrombin/Thrombin
- Fibrinogen/Fibrin

INR: ABNORMALITIES

PROLONGED

DRUGS

- Vit-K antagonists.
- CYP antagonists
 - Warfarin
- Apixaban (DOAC)
- Edoxaban (DOAC)

BIOLOGY

- Inflammation
- Liver Disease
- FVII deficiency
- FVII inhibitor
- Malnutrition

SHORT

PREANALYTICAL

Can be shorted by preactivation during a blood draw.

BIOLOGICAL

Can be shorted by hyperfibrinogenaemia

These are uncommon.

INR: DIFFERENTIAL DIAGNOSIS.

		APTR	Other Tests
Drugs	Vitamin K antagonist	↑ (mild) or normal	None.
	DOACS	↑	Specific levels can be tested.
Inflammation	Acute Phase Response	↑ (mild) or normal	CRP, bacterial cultures etc.
	Sepsis/DIC.	↑ or ↑↑ in later stages.	D-dimer, Fibrinogen. As above.
Liver Insufficiency	Liver Disease	↑ or ↑↑ in later stages.	ALT , AST, GGT, Bilirubin, Albumin
	Malnutrition	↑ in later stages.	Liver function may be deranged, vitamin levels will be reduced.
Deficiency or Inhibitor		Normal if FVII, ↑ if common	Factor levels and inhibitor screening.

ACTIVATED PARTIAL THROMBOPLASTIN RATIO: KEY FACTS


APT TIME

Plasma is incubated with a “foreign” substance and then calcium is added.

APT RATIO

There is no official conversion for APTR. However, to avoid changing reference ranges, a ratio is used.

$$\text{APTR} = (\text{APTR}^{\text{patient}} / \text{APTR}^{\text{normal}})$$




CLINICAL RELEVANCE?

Measures the **Intrinsic** and **common** pathways. Used to assess a wider range of clotting factors.

FACTORS ASSESSED

- FVIII
- FIX
- FXI
- FXII
- FX, FV, Prothrombin, Fibrinogen

APTR: ABNORMALITIES



APTR: DIFFERENTIAL DIAGNOSIS.

		INR	Other Tests
Drugs	Heparin/Clexane	Normal or mild ↑	Anti-Xa levels
	DOACS	↑	Specific levels can be tested.
Deficiency or Inhibitor		Normal (unless common)	Specific factor levels and inhibitor screens.
Lupus Anticoagulant		Normal	Dilute Russel Viper Venom Time etc.
Von Willebrand's Disease		Normal	FVIII levels, vWF antigen and activity
Liver Insufficiency	Liver Disease	↑↑	ALT , AST, GGT, Bilirubin, Albumin
	Malnutrition	↑↑	Liver function may be deranged, vitamin levels will be reduced.
Inflammation		↑ or ↑↑ in cases of sepsis or DIC	CRP, bacterial cultures etc. D-dimer, Fibrinogen. As above.



WHAT CAN
YOU DO?



THE IMPORTANCE OF HISTORY

```
Clinical Info:  
?TB. CLEX \  
Specimen No : HQ823269C
```

CLINICAL DETAILS

Drug names are contained in the current clinical details. Also, check locations e.g. ACEM or C5 for further clues!

PAST TESTING

Have they had specialist coagulation testing done? What were the results? Have they ever been under haematology?

Clinical Details

Past Clotting

Previous Testing

Previous HQ

PAST CLOTTING

Previous, and recent clotting may have the drug name. It also illustrates the trend of results.

PREVIOUS HQ

Has a doctor (or me!) done your work for you?

WHAT PROGRAMMES DO WE HAVE?

A QUICKER CAVEAT!

Just because the patient is recorded as being on an anticoagulant in their history- doesn't mean they still are!

MINES

VIEW

Minestrone information the hospital current me

(dated) tells the patient's y in the al.

MINESTRONE

Clinical Documents

EBQAF 22 Mar 2023 Queen Alexandra Hospital

[Redacted]

4 Allendale Avenue, Emsworth, Hants, PO10 7TJ

Oncology closed at 18pm

Clinical Documents

Allergy Status

Allergies	Reaction	Type
NSAIDS	Blood Disorder	Drug Allergy

Notes:

TTO-
12/01/23 TTO dispensed
13/01/23 12:00 TTO needs updating as bisoprolol dose further reduced + fludrocortisone started. TTO uncompleted

Bisoprolol dose reduced
Folic acid started (folate 2.8 on 05/01/23) - for 4 months
Ferrous fumarate started

Warfarin-Warfarin restarted on 04/01/23 at the usual dosing:
4mg on Monday and Friday
5mg on Tuesday, Wednesday, Thursday, Saturday and Sunday

INR target 3 to 4
Indication: mechanical mitral valve replacement
07/01/23: INR 2.9
09/01/23: INR 3.9

Inpatient Final Discharge letter
16/01/2023 - Clinical Oncology

Consultant Dr Daniel Bloomfield

BEDVIEW

(MR)

Born: 05/09/1967 (55) Gender: M NHS No:

District No: 05096723

Consultant: Dr H AL-CHAMALI (C7084413)

Specialty: Clinical Oncology

Summary

Clinical Note

Discharge Note

Record Of Care

Referrals

Interactions

Risk Assessments

Clinical eHandover

DigiMeds

Prescriptions

Changes

Diagnosis:

5days 17hr 24mins



NEUTROPENIA

Had trial chemotherapy last week 31/3/23
LBO secondary to metastatic rectal Ca with pulmonary/liver mets. BG: AF, PE on

ivaroxaban

Treatment Plan:

5hr 2mins

I/O monitoring
syringe drive[x]
FILGRASTIM
Quad swab[x]
awaits oncology bed

Infections:

1days 21hr 10mins

Neutropenia - KEEP IN CUBICLE

Pressure Ulcers:

5days 5hr 14mins

Intact

50:50 MIX

INR

CORRECTS

- Suggests a lack of FVIII which may be congenital or aquired.

DOESN'T CORRECT

- FVII Inhibitor
- Drug inhibition

APTR

CORRECTS

- Possible lack of many clotting factors, which may be congenital or aquired.

DOESN'T CORRECT

- Factor Inhibitor
- Drug inhibition
- Lupus Anticoagulation

WHEN TO ACTION

HIGH INR

INR >6.0 for warfarin patients should be phoned.



50:50 MIX

Should be done if INR/APTR >1.4 with no cause.

HIGH APTR

>4.0 for any reason require phoning. Place on HQ if no cause.



DIC

Abnormal clotting with clinical details e.g. sepsis, may suggest DIC.

THANKS!

Do you have any questions?

Jennifer.mills@porthosp.nhs.uk
023 92 28 5774

CREDITS: This presentation template was created by Slidesgo, including icons by Flaticon, and infographics & images by Freepik and illustrations

Please keep this slide for attribution

